Beximco Pharmaceuticals Limited
BXP.L · LSE
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Revenue | £44,392 | £39,267 | £34,669 | £29,494 |
| % Growth | 13.1% | 13.3% | 17.5% | – |
| Cost of Goods Sold | £24,758 | £22,164 | £18,855 | £15,570 |
| Gross Profit | £19,634 | £17,102 | £15,814 | £13,924 |
| % Margin | 44.2% | 43.6% | 45.6% | 47.2% |
| R&D Expenses | £3 | £363 | £281 | £235 |
| G&A Expenses | £709 | £668 | £1,163 | £897 |
| SG&A Expenses | £5,596 | £5,247 | £8,913 | £7,273 |
| Sales & Mktg Exp. | £4,886 | £4,579 | £7,750 | £6,376 |
| Other Operating Expenses | £5,361 | £4,290 | -£256 | -£342 |
| Operating Expenses | £10,960 | £9,899 | £8,938 | £7,166 |
| Operating Income | £8,674 | £7,216 | £6,901 | £6,651 |
| % Margin | 19.5% | 18.4% | 19.9% | 22.5% |
| Other Income/Exp. Net | -£1,149 | -£1,147 | -£195 | -£273 |
| Pre-Tax Income | £7,525 | £6,069 | £6,687 | £6,378 |
| Tax Expense | £1,659 | £1,544 | £1,688 | £1,212 |
| Net Income | £5,830 | £4,614 | £5,123 | £5,128 |
| % Margin | 13.1% | 11.8% | 14.8% | 17.4% |
| EPS | 13.07 | 10.34 | 11.48 | 11.49 |
| % Growth | 26.4% | -9.9% | -0.1% | – |
| EPS Diluted | 13.07 | 10.34 | 11.48 | 11.49 |
| Weighted Avg Shares Out | 446 | 446 | 446 | 446 |
| Weighted Avg Shares Out Dil | 446 | 446 | 446 | 446 |
| Supplemental Information | – | – | – | – |
| Interest Income | £16 | £6 | £3 | £2 |
| Interest Expense | £1,160 | £1,286 | £1,002 | £859 |
| Depreciation & Amortization | £1,994 | £2,061 | £1,667 | £204 |
| EBITDA | £10,640 | £9,371 | £8,247 | £7,387 |
| % Margin | 24% | 23.9% | 23.8% | 25% |